FairJourney Biologics Appoints Former Evotec CEO Werner Lanthaler to Lead Antibody Discovery Platform
核心洞察
FairJourney Biologics (搜索) has appointed Dr. Werner Lanthaler, former 15-year CEO of Evotec SE, as its new Chief Executive Officer to strengthen the company's global position in antibody discovery and development.
Founder António Parada will transition from CEO to the Supervisory Board after nearly 14 years of leadership, focusing on driving the company's innovation strategy.
Lanthaler emphasized that shared data- and AI-driven innovation platforms will be critical to accelerating drug discovery while reducing development timelines and costs.
FairJourney Biologics (搜索) S.A. (FJBio) has appointed Dr. Werner Lanthaler as Chief Executive Officer to strengthen its global position as a highly efficient partner for antibody discovery and development. The leadership transition comes as founder António Parada steps back from day-to-day operations after nearly 14 years at the helm, moving to focus on innovation strategy as a member of the Supervisory Board.
Industry Veteran Takes the Helm
Dr. Lanthaler brings extensive biopharmaceutical leadership experience to FairJourney Biologics (搜索). He served as CEO of Evotec SE for 15 years, where he transformed the company into a global leader in drug discovery, particularly in precision medicine. Prior to Evotec, he served as CFO of Intercell (搜索), where he was responsible for the company's IPO and the successful market launch of its vaccines.
Throughout his career, Lanthaler has forged collaborations with global pharmaceutical, biotechnology, and academic institutions to drive commercial success and long-term growth.
Vision for AI-Driven Drug Discovery
"Shared data- and AI-driven innovation platforms will be critical to accelerating drug discovery while reducing development timelines and costs," said Lanthaler. "FairJourney Biologics (搜索) is best positioned to be the global leader in delivering significant efficiency gains resulting from the entire 'Gene to Clone' process for its partners. I am honored to lead FJBio into its next growth phase."
Strategic Transition and Growth Focus
The appointment reflects FairJourney Biologics (搜索)' evolution from what Pascal Noth, Head of Healthcare Lifesciences Europe at Partners Group (搜索), described as "a bold idea in Porto into a global innovator." Noth expressed confidence that under Lanthaler's leadership, the company will build on its foundation and continue to deliver transformative impact in antibody discovery.
António Parada emphasized the company's future direction, stating: "FairJourney Biologics (搜索) is just at the beginning of its mission to lead the field of rapid antibody development. Innovation will hold a central role in helping to drive transformational benefits to our partners."
The leadership change positions FairJourney Biologics (搜索) to accelerate its growth trajectory as an integrated powerhouse in efficient antibody discovery and development, leveraging advanced technologies to serve pharmaceutical partners globally.